Excitotoxicity in Huntington disease

Clinical Neuroscience Research

Volumn 3, Issue 3, 2003, Pages 121-128

  Raymond, Lynn A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

N methyl D aspartate receptor; Patch clamp recording; Striatal neuron

Indexed keywords

CALCIUM ION; CREATINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; HUNTINGTIN; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; REMACEMIDE; RILUZOLE; THIOCTIC ACID; UBIDECARENONE; WATER;

AMINO TERMINAL SEQUENCE; ANIMAL BEHAVIOR; BEHAVIOR DISORDER; CALCIUM TRANSPORT; CELL DAMAGE; CELL DEATH; CELL LINE; CELL POPULATION; CORPUS STRIATUM; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; GENE IDENTIFICATION; GENETIC CODE; HUMAN; HUNTINGTON CHOREA; MEMBRANE CURRENT; MOUSE; NERVE DEGENERATION; NERVE EXCITABILITY; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NEUROTRANSMITTER UPTAKE; NONHUMAN; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RODENT; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT; WATER TRANSPORT;

EID: 0141493677     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(03)00054-9     Document Type: Article

References (120)

1. Rothman S.M. Olney J.W. Excitotoxicity and the NMDA receptor - still lethal after 8 years Trends Neurosci 18 1995 57-58
2. Hollmann M. Heinemann S. Cloned glutamate receptors Annu Rev Neurosci 17 1994 31-108
3. Dingledine R. Borges K. Bowie D. Traynelis S.F. The glutamate receptor ion channels Pharmacol Rev 51 1999 7-61
4. Rossi D.J. Oshima T. Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake Nature 403 2000 316-321
5. Simon R.P. Swan J.H. Griffiths T. Meldrum B.S. Blockade of N-methyl-d-aspartate receptors may protect against ischemic damage in the brain Science 226 1984 850-852
6. Kochhar A. Zivin J.A. Lyden P.D. Mazzarella V. Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia Arch Neurol 45 1988 148-153
7. Park C.K. Nehls D.G. Graham D.I. Teasdale G.M. McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat Ann Neurol 24 1988 543-551
8. Turski L. Bressler K. Rettig K.J. Loschmann P.A. Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-aspartate antagonists Nature 349 1991 414-418
9. Tabatabaei A. Perry T.L. Hansen S. Krieger C. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice Neurosci Lett 141 1992 192-194
10. Srivastava R. Brouillet E. Beal M.F. Storey E. Hyman B.T. Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss Neurobiol Aging 14 1993 295-301
11. Rothstein J.D. Tsai G. Kuncl R.W. et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis Ann Neurol 28 1990 18-25
12. Rothstein J.D. Martin L.J. Kuncl R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis N Engl J Med 326 1992 1464-1468
13. Rothstein J.D. Van Kammen M. Levey A.I. Martin L.J. Kuncl R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis Ann Neurol 38 1995 73-84
14. Lacomblez L. Bensimon G. Leigh P.N. et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II Neurology 47 1996 S242-S250
15. Lacomblez L. Bensimon G. Leigh P.N. Guillet P. Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II Lancet 347 1996 1425-1431
16. Verhagen Metman L. Del Dotto P. Blanchet P.J. van den Munckhof P. Chase T.N. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease Amino Acids 14 1998 75-82
17. Merims D. Ziv I. Djaldetti R. Melamed E. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease Lancet 353 1999 1764-1765
18. Merello M. Nouzeilles M.I. Cammarota A. Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study Clin Neuropharmacol 22 1999 273-276
19. Shoulson I. Penney J. McDermott M. et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease Neurology 56 2001 455-462
20. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2002;2:CD001447. Review.
21. Vonsattel J.P. DiFiglia M. Huntington disease J Neuropathol Exp Neurol 57 1998 369-384
22. Coyle J.T. Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea Nature 263 1976 244-246
23. McGeer E.G. McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids Nature 263 1976 517-519
24. McGeer E.G. McGeer P.L. Singh K. Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract Brain Res 139 1978 381-383
25. Beal M.F. Kowall N.W. Ellison D.W. Mazurek M.F. Swartz K.J. Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid Nature 321 1986 168-171
26. Beal M.F. Kowall N.W. Ferrante R.J. Cippolloni P.B. Quinolinic acid striatal lesions in primates as a model of Huntington's disease Ann Neurol 26 1989 137
27. Hantraye P. Riche D. Maziere M. Isacson O. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon Exp Neurol 108 1990 91-104
28. Ferrante R.J. Kowall N.W. Cipolloni P.B. Storey E. Beal M.F. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization Exp Neurol 119 1993 46-71
29. Dawbarn D. De Quidt M.E. Emson P.C. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease Brain Res 340 1985 251-260
30. Ferrante R.J. Kowall N.W. Beal M.F. Richardson E.P.Jr Bird E.D. Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease Science 230 1985 561-563
31. Graveland G.A. Williams R.S. DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease Science 227 1985 770-773
32. Ferrante R.J. Kowall N.W. Beal M.F. Martin J.B. Bird E.D. Richardson E.P.Jr Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease J Neuropathol Exp Neurol 46 1987 12-27
33. Ferrante R.J. Beal M.F. Kowall N.W. Richardson E.P.Jr Martin J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease Brain Res 411 1987 162-166
34. Goto S. Hirano A. Rojas-Corona R.R. An immunohistochemical investigation of the human neostriatum in Huntington's disease Ann Neurol 25 1989 298-304
35. Sanberg P.R. Calderon S.F. Giordano M. Tew J.M. Norman A.B. The quinolinic acid model of Huntington's disease: locomotor abnormalities Exp Neurol 105 1989 45-53
36. Beal M.F. Brouillet E. Jenkins B.G. et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid J Neurosci 13 1993 4181-4192
37. Greene J.G. Porter R.H. Eller R.V. Greenamyre J.T. Inhibition of succinate dehydrogenase by malonic acid produces an 'excitotoxic' lesion in rat striatum J Neurochem 61 1993 1151-1154
38. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971-983
39. Hackam A.S. Yassa A.S. Singaraja R. et al. Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain J Biol Chem 275 2000 41299-41308
40. Cattaneo E. Rigamonti D. Goffredo D. Zuccato C. Squitieri F. Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research Trends Neurosci 24 2001 182-188
41. Rigamonti D. Bauer J.H. De-Fraja C. et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3 J Neurosci 20 2000 3705-3713
42. Leavitt B.R. Guttman J.A. Hodgson J.G. et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo Am J Hum Genet 68 2001 313-324
43. Wellington C.L. Ellerby L.M. Gutekunst C.A. et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease J Neurosci 22 2002 7862-7872
44. MacDonald M.E. Gusella J.F. Huntington's disease: translating a CAG repeat into a pathogenic mechanism Curr Opin Neurobiol 6 1996 638-643
45. Ross C.A. When more is less: pathogenesis of glutamine repeat neurodegenerative diseases Neuron 15 1995 493-496
46. Davies S.W. Turmaine M. Cozens B.A. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537-548
47. DiFiglia M. Sapp E. Chase K.O. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990-1993
48. Scherzinger E. Lurz R. Turmaine M. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo Cell 90 1997 549-558
49. Cooper J.K. Schilling G. Peters M.F. et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture Hum Mol Genet 7 1998 783-790
50. Hackam A.S. Wellington C.L. Hayden M.R. The fatal attraction of polyglutamine-containing proteins Clin Genet 53 1998 233-242
51. Li S.H. Li X.J. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats Hum Mol Genet 7 1998 777-782
52. Martindale D. Hackam A. Wieczorek A. et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates Nat Genet 18 1998 150-154
53. Goldberg Y.P. Nicholson D.W. Rasper D.M. et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract [see comments] Nat Genet 13 1996 442-449
54. Wellington C.L. Ellerby L.M. Hackam A.S. et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract J Biol Chem 273 1998 9158-9167
55. Wellington C.L. Singaraja R. Ellerby L. et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and non-neuronal cells J Biol Chem 275 2000 19831-19838
56. Kim Y.J. Yi Y. Sapp E. et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis Proc Natl Acad Sci USA 98 2001 12784-12789
57. Gafni J. Ellerby L.M. Calpain activation in Huntington's disease J Neurosci 22 2002 4842-4849
58. Goffredo D. Rigamonti D. Tartari M. et al. Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons J Biol Chem 277 2002 39594-39598
59. Ona V.O. Li M. Vonsattel J.P. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease [see comments] Nature 399 1999 263-267
60. Sanchez I. Xu C.J. Juo P. Kakizaka A. Blenis J. Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats [see comments] Neuron 22 1999 623-633
61. Chen M. Ona V.O. Li M. et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease Nat Med 6 2000 797-801
62. Reddy P.H. Williams M. Tagle D.A. Recent advances in understanding the pathogenesis of Huntington's disease Trends Neurosci 22 1999 248-255
63. Mangiarini L. Sathasivam K. Seller M. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 1996 493-506
64. Hansson O. Peters N.A. Leist M. Nicotera P. Castilho R.F. Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity Proc Natl Acad Sci USA 96 1999 8727-8732
65. Hansson O. Guatteo E. Mercuri N.B. et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene Eur J Neurosci 14 2001 1492-1504
66. Hansson O. Castilho R.F. Korhonen L. Lindholm D. Bates G.P. Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length J Neurochem 78 2001 694-703
67. Petersen A. Hansson O. Puschban Z. et al. Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine Eur J Neurosci 14 2001 1425-1435
68. Reddy P.H. Williams M. Charles V. et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA Nat Genet 20 1998 198-202
69. Hodgson J.G. Agopyan N. Gutekunst C.A. et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration Neuron 23 1999 181-192
70. Sapp E. Penney J. Young A. Aronin N. Vonsattel J.P. DiFiglia M. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease J Neuropathol Exp Neurol 58 1999 165-173
71. Zeron M.M. Hansson O. Chen N. et al. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease Neuron 33 2002 849-860
72. Cepeda C. Hurst R.S. Calvert C.R. et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease J Neurosci 23 2003 961-969
73. Gutekunst C.A. Li S.H. Yi H. et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology J Neurosci 19 1999 2522-2534
74. Laforet G.A. Sapp E. Chase K. et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease J Neurosci 21 2001 9112-9123
75. Li H. Li S.H. Johnston H. Shelbourne P.F. Li X.J. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity Nat Genet 25 2000 385-389
76. Levine M.S. Klapstein G.J. Koppel A. et al. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease J Neurosci Res 58 1999 515-532
77. Cepeda C. Ariano M.A. Calvert C.R. et al. NMDA receptor function in mouse models of Huntington disease J Neurosci Res 66 2001 525-539
78. Li L, Fan M, Icton C, et al. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging (in press).
79. Klapstein G.J. Fisher R.S. Zanjani H. et al. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice J Neurophysiol 86 2001 2667-2677
80. Panov A.V. Gutekunst C.A. Leavitt B.R. et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines Nat Neurosci 5 2002 731-736
81. Tymianski M. Charlton M.P. Carlen P.L. Tator C.H. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons J Neurosci 13 1993 2085-2104
82. Peng T.I. Greenamyre J.T. Privileged access to mitochondria of calcium influx through N-methyl-d-aspartate receptors Mol Pharmacol 53 1998 974-980
83. Sattler R. Charlton M.P. Hafner M. Tymianski M. Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity J Neurochem 71 1998 2349-2364
84. Williams K. Separating dual effects of zinc at recombinant N-methyl-d-aspartate receptors Neurosci Lett 215 1996 9-12
85. Chen N. Moshaver A. Raymond L.A. Differential sensitivity of recombinant N-methyl-d-aspartate receptor subtypes to zinc inhibition Mol Pharmacol 51 1997 1015-1023
86. Paoletti P. Ascher P. Neyton J. High-affinity zinc inhibition of NMDA NR1-NR2A receptors [published erratum appears in J Neurosci 1997 Oct 15;17(20):following table of contents] J Neurosci 17 1997 5711-5725
87. Wyllie D.J. Behe P. Colquhoun D. Single-channel activations and concentration jumps: comparison of recombinant NR1a/NR2A and NR1a/NR2D NMDA receptors [published erratum appears in J Physiol (Lond) 1998 Nov 1;512(Pt 3):939] J Physiol (Lond) 510 1998 1-18
88. Chen N. Luo T. Raymond L.A. Subtype-dependence of NMDA receptor channel open probability J Neurosci 19 1999 6844-6854
89. Cepeda C. Itri J.N. Flores-Hernandez J. Hurst R.S. Calvert C.R. Levine M.S. Differential sensitivity of medium- and large-sized striatal neurons to NMDA but not kainate receptor activation in the rat Eur J Neurosci 14 2001 1577-1589
90. Landwehrmeyer G.B. Standaert D.G. Testa C.M. Penney J.B. Jr Young A.B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum J Neurosci 15 1995 5297-5307
91. Ghasemzadeh M.B. Sharma S. Surmeier D.J. Eberwine J.H. Chesselet M.F. Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study Mol Pharmacol 49 1996 852-859
92. Rigby M. Le Bourdelles B. Heavens R.P. et al. The messenger RNAs for the N-methyl-d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain Neuroscience 73 1996 429-447
93. Christie J.M. Jane D.E. Monaghan D.T. Native N-methyl-d-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites J Pharmacol Exp Ther 292 2000 1169-1174
94. Chen N. Luo T. Wellington C. et al. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin J Neurochem 72 1999 1890-1898
95. Zeron M.M. Chen N. Moshaver A. et al. Mutant huntingtin enhances excitotoxic cell death Mol Cell Neurosci 17 2001 41-53
96. Vallano M.L. Lambolez B. Audinat E. Rossier J. Neuronal activity differentially regulates NMDA receptor subunit expression in cerebellar granule cells J Neurosci 16 1996 631-639
97. Monyer H. Burnashev N. Laurie D.J. Sakmann B. Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors Neuron 12 1994 529-540
98. Tovar K.R. Westbrook G.L. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro J Neurosci 19 1999 4180-4188
99. Barria A. Malinow R. Subunit-specific NMDA receptor trafficking to synapses Neuron 35 2002 345-353
100. Chapman D.E. Keefe K.A. Wilcox K.S. Evidence for functionally distinct synaptic NMDA receptors in ventromedial versus dorsolateral striatum J Neurophysiol 89 2003 69-80
101. Husi H. Ward M.A. Choudhary J.S. Blackstock W.P. Grant S.G. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes Nat Neurosci 3 2000 661-669
102. Sheng M. Pak D.T. Ligand-gated ion channel interactions with cytoskeletal and signaling proteins Annu Rev Physiol 62 2000 755-778
103. Walikonis R.S. Jensen O.N. Mann M. Provance D.W. Jr Mercer J.A. Kennedy M.B. Identification of proteins in the postsynaptic density fraction by mass spectrometry J Neurosci 20 2000 4069-4080
104. Husi H. Grant S.G. Isolation of 2000-kDa complexes of N-methyl-d-aspartate receptor and postsynaptic density 95 from mouse brain J Neurochem 77 2001 281-291
105. Sattler R. Xiong Z. Lu W.Y. Hafner M. MacDonald J.F. Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein Science 284 1999 1845-1848
106. Sattler R. Xiong Z. Lu W.Y. MacDonald J.F. Tymianski M. Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity J Neurosci 20 2000 22-33
107. Aarts M. Liu Y. Liu L. et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions Science 298 2002 846-850
108. Dawson V.L. Dawson T.M. Bartley D.A. Uhl G.R. Snyder S.H. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures J Neurosci 13 1993 2651-2661
109. Sattler R. Tymianski M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death Mol Neurobiol 24 2001 107-129
110. Sun Y. Savanenin A. Reddy P.H. Liu Y.F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-d-aspartate receptors via post-synaptic density 95 J Biol Chem 276 2001 24713-24718
111. Rosenmund C. Westbrook G.L. Calcium-induced actin depolymerization reduces NMDA channel activity Neuron 10 1993 805-814
112. Allison D.W. Gelfand V.I. Spector I. Craig A.M. Role of actin in anchoring postsynaptic receptors in cultured hippocampal neurons: differential attachment of NMDA versus AMPA receptors J Neurosci 18 1998 2423-2436
113. Zhang S. Ehlers M.D. Bernhardt J.P. Su C.T. Huganir R.L. Calmodulin mediates calcium-dependent inactivation of N-methyl-d-aspartate receptors Neuron 21 1998 443-453
114. 2+-dependent inactivation of NMDA receptors J Neurosci 19 1999 1165-1178
115. Mary V. Wahl F. Stutzmann J.M. Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission Neurosci Lett 201 1995 92-96
116. Andreassen O.A. Dedeoglu A. Ferrante R.J. et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease Neurobiol Dis 8 2001 479-491
117. Andreassen O.A. Ferrante R.J. Dedeoglu A. Beal M.F. Lipoic acid improves survival in transgenic mouse models of Huntington's disease Neuroreport 12 2001 3371-3373
118. Ferrante R.J. Andreassen O.A. Dedeoglu A. et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease J Neurosci 22 2002 1592-1599
119. Kremer B. Clark C.M. Almqvist E.W. et al. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial Neurology 53 1999 1000-1011
120. Group H.S. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease Neurology 57 2001 397-404